U.S. markets closed

Perrigo Company plc (0Y5E.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
75.69+21.80 (+40.45%)
At close: 11:52AM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close53.89
Open54.57
Bid0.00 x 0
Ask0.00 x 0
Day's Range54.57 - 54.57
52 Week Range54.57 - 54.57
Volume80
Avg. VolumeN/A
Market Cap10.52B
Beta (5Y Monthly)1.16
PE Ratio (TTM)43.20
EPS (TTM)1.75
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • MarketWatch

      Perrigo shares dip premarket on news to voluntarily recall albuterol sulfate inhalation aerosols due to clogging concerns

      Perrigo Company plc shares slid 3% in premarket trade Thursday, after the company said it's voluntarily recalling albuterol sulfate inhalation aerosols over concerns that some may not dispense properly due to clogging. The Dublin-based maker of over-the-counter and generic health products already halted production and distribution of the aerosols. "Corrective action plans are underway and a definitive timeline for product reintroduction has not been determined at this time," the company said in a statement. Perrigo is expecting to book a charge of $18 million to $22 million in the third quarter relating to the recall, and has not booked any revenue from the product since August. It reiterated its guidance for fiscal 2020 adjusted per-share earnings to range from $3.95 to $4.15, citing strong demand in the consumer self-care Americas business and faster-than-expected recovery in consumer self-care international and base prescription businesses that were hurt by the pandemic. Shares have fallen 3.5% in the year to date, while the S&P 500 has gained 4.8%.

    • Perrigo Voluntarily Recalls Albuterol Sulfate Inhalation Aerosol; Reaffirms 2020 Guidance
      PR Newswire

      Perrigo Voluntarily Recalls Albuterol Sulfate Inhalation Aerosol; Reaffirms 2020 Guidance

      Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S. nationwide recall of albuterol sulfate inhalation aerosol to the retail level after previously halting production and distribution. These actions are being taken out of an abundance of caution as a result of complaints that some units may not dispense due to clogging. Perrigo's generic albuterol sulfate inhalation aerosol was developed in partnership with and manufactured by Catalent Pharma Solutions.

    • Top Pharmaceutical Stocks for Q4 2020
      Investopedia

      Top Pharmaceutical Stocks for Q4 2020

      These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.